This suggests that AD pathology may be more widespread in patients who report cognitive impairment (so that we are more likely to see both β-amyloid and tau in a small biopsy), even if the local density of AD pathology in these biopsies is not significantly higher compared to patients who report no cognitive impairment. Here, MAPT is linked to Alzheimer disease.